TY - JOUR A1 - Bousquet, J. A1 - Farrell, J. A1 - Crooks, G. A1 - Hellings, P. A1 - Bel, E. H. A1 - Bewick, M. A1 - Chavannes, N. H. A1 - Correia de Sousa, J. A1 - Cruz, A. A. A1 - Haahtela, T. A1 - Joos, G. A1 - Khaltaev, N. A1 - Malva, J. A1 - Muraro, A. A1 - Nogues, M. A1 - Palkonen, S. A1 - Pedersen, S. A1 - Robalo-Cordeiro, C. A1 - Samolinski, B. A1 - Strandberg, T. A1 - Valiulis, A. A1 - Yorgancioglu, A. A1 - Zuberbier, T. A1 - Bedbrook, A. A1 - Aberer, W. A1 - Adachi, M. A1 - Agusti, A. A1 - Akdis, C. A. A1 - Akdis, M. A1 - Ankri, J. A1 - Alonso, A. A1 - Annesi-Maesano, I. A1 - Ansotegui, I. J. A1 - Anto, J. M. A1 - Arnavielhe, S. A1 - Arshad, H. A1 - Bai, C. A1 - Baiardini, I. A1 - Bachert, C. A1 - Baigenzhin, A. K. A1 - Barbara, C. A1 - Bateman, E. D. A1 - Beghé, B. A1 - Ben Kheder, A. A1 - Bennoor, K. S. A1 - Benson, M. A1 - Bergmann, K. C. A1 - Bieber, T. A1 - Bindslev-Jensen, C. A1 - Bjermer, L. A1 - Blain, H. A1 - Blasi, F. A1 - Boner, A. L. A1 - Bonini, M. A1 - Bonini, S. A1 - Bosnic-Anticevitch, S. A1 - Boulet, L. P. A1 - Bourret, R. A1 - Bousquet, P. J. A1 - Braido, F. A1 - Briggs, A. H. A1 - Brightling, C. E. A1 - Brozek, J. A1 - Buhl, R. A1 - Burney, P. G. A1 - Bush, A. A1 - Caballero-Fonseca, F. A1 - Caimmi, D. A1 - Calderon, M. A. A1 - Calverley, P. M. A1 - Camargos, P. A. M. A1 - Canonica, G. W. A1 - Camuzat, T. A1 - Carlsen, K. H. A1 - Carr, W. A1 - Carriazo, A. A1 - Casale, T. A1 - Cepeda Sarabia, A. M. A1 - Chatzi, L. A1 - Chen, Y. Z. A1 - Chiron, R. A1 - Chkhartishvili, E. A1 - Chuchalin, A. G. A1 - Chung, K. F. A1 - Ciprandi, G. A1 - Cirule, I. A1 - Cox, L. A1 - Costa, D. J. A1 - Custovic, A. A1 - Dahl, R. A1 - Dahlen, S. E. A1 - Darsow, U. A1 - De Carlo, G. A1 - De Blay, F. A1 - Dedeu, T. A1 - Deleanu, D. A1 - De Manuel Keenoy, E. A1 - Demoly, P. A1 - Denburg, J. A. A1 - Devillier, P. A1 - Didier, A. A1 - Dinh-Xuan, A. T. A1 - Djukanovic, R. A1 - Dokic, D. A1 - Douagui, H. A1 - Dray, G. A1 - Dubakiene, R. A1 - Durham, S. R. A1 - Dykewicz, M. S. A1 - El-Gamal, Y. A1 - Emuzyte, R. A1 - Fabbri, L. M. A1 - Fletcher, M. A1 - Fiocchi, A. A1 - Fink Wagner, A. A1 - Fonseca, J. A1 - Fokkens, W. J. A1 - Forastiere, F. A1 - Frith, P. A1 - Gaga, M. A1 - Gamkrelidze, A. A1 - Garces, J. A1 - Garcia-Aymerich, J. A1 - Gemicioğlu, B. A1 - Gereda, J. E. A1 - González Diaz, S. A1 - Gotua, M. A1 - Grisle, I. A1 - Grouse, L. A1 - Gutter, Z. A1 - Guzmán, M. A. A1 - Heaney, L. G. A1 - Hellquist-Dahl, B. A1 - Henderson, D. A1 - Hendry, A. A1 - Heinrich, J. A1 - Heve, D. A1 - Horak, F. A1 - Hourihane, J. O’. B. A1 - Howarth, P. A1 - Humbert, M. A1 - Hyland, M. E. A1 - Illario, M. A1 - Ivancevich, J. C. A1 - Jardim, J. R. A1 - Jares, E. J. A1 - Jeandel, C. A1 - Jenkins, C. A1 - Johnston, S. L. A1 - Jonquet, O. A1 - Julge, K. A1 - Jung, K. S. A1 - Just, J. A1 - Kaidashev, I. A1 - Kaitov, M. R. A1 - Kalayci, O. A1 - Kalyoncu, A. F. A1 - Keil, T. A1 - Keith, P. K. A1 - Klimek, L. A1 - Koffi N’Goran, B. A1 - Kolek, V. A1 - Koppelman, G. H. A1 - Kowalski, M. L. A1 - Kull, I. A1 - Kuna, P. A1 - Kvedariene, V. A1 - Lambrecht, B. A1 - Lau, S. A1 - Larenas‑Linnemann, D. A1 - Laune, D. A1 - Le, L. T. T. A1 - Lieberman, P. A1 - Lipworth, B. A1 - Li, J. A1 - Lodrup Carlsen, K. A1 - Louis, R. A1 - MacNee, W. A1 - Magard, Y. A1 - Magnan, A. A1 - Mahboub, B. A1 - Mair, A. A1 - Majer, I. A1 - Makela, M. J. A1 - Manning, P. A1 - Mara, S. A1 - Marshall, G. D. A1 - Masjedi, M. R. A1 - Matignon, P. A1 - Maurer, M. A1 - Mavale‑Manuel, S. A1 - Melén, E. A1 - Melo‑Gomes, E. A1 - Meltzer, E. O. A1 - Menzies‑Gow, A. A1 - Merk, H. A1 - Michel, J. P. A1 - Miculinic, N. A1 - Mihaltan, F. A1 - Milenkovic, B. A1 - Mohammad, G. M. Y. A1 - Molimard, M. A1 - Momas, I. A1 - Montilla‑Santana, A. A1 - Morais‑Almeida, M. A1 - Morgan, M. A1 - Mösges, R. A1 - Mullol, J. A1 - Nafti, S. A1 - Namazova‑Baranova, L. A1 - Naclerio, R. A1 - Neou, A. A1 - Neffen, H. A1 - Nekam, K. A1 - Niggemann, B. A1 - Ninot, G. A1 - Nyembue, T. D. A1 - O’Hehir, R. E. A1 - Ohta, K. A1 - Okamoto, Y. A1 - Okubo, K. A1 - Ouedraogo, S. A1 - Paggiaro, P. A1 - Pali‑Schöll, I. A1 - Panzner, P. A1 - Papadopoulos, N. A1 - Papi, A. A1 - Park, H. S. A1 - Passalacqua, G. A1 - Pavord, I. A1 - Pawankar, R. A1 - Pengelly, R. A1 - Pfaar, O. A1 - Picard, R. A1 - Pigearias, B. A1 - Pin, I. A1 - Plavec, D. A1 - Poethig, D. A1 - Pohl, W. A1 - Popov, T. A. A1 - Portejoie, F. A1 - Potter, P. A1 - Postma, D. A1 - Price, D. A1 - Rabe, K. F. A1 - Raciborski, F. A1 - Radier Pontal, F. A1 - Repka‑Ramirez, S. A1 - Reitamo, S. A1 - Rennard, S. A1 - Rodenas, F. A1 - Roberts, J. A1 - Roca, J. A1 - Rodriguez Mañas, L. A1 - et al, T1 - Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) JF - Clinical and Translational Allergy N2 - Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing. KW - EIP on AHA KW - European Innovation Partnership on Active and Healthy Ageing KW - AIRWAYS ICPs KW - MACVIA KW - Scaling up KW - Chronic respiratory diseases KW - ARIA Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-166874 VL - 6 IS - 29 ER - TY - JOUR A1 - Edgecock, T. R. A1 - Caretta, O. A1 - Davenne, T. A1 - Densam, C. A1 - Fitton, M. A1 - Kelliher, D. A1 - Loveridge, P. A1 - Machida, S. A1 - Prior, C. A1 - Rogers, C. A1 - Rooney, M. A1 - Thomason, J. A1 - Wilcox, D. A1 - Wildner, E. A1 - Efthymiopoulos, I. A1 - Garoby, R. A1 - Gilardoni, S. A1 - Hansen, C. A1 - Benedetto, E. A1 - Jensen, E. A1 - Kosmicki, A. A1 - Martini, M. A1 - Osborne, J. A1 - Prior, G. A1 - Stora, T. A1 - Melo Mendonca, T. A1 - Vlachoudis, V. A1 - Waaijer, C. A1 - Cupial, P. A1 - Chancé, A. A1 - Longhin, A. A1 - Payet, J. A1 - Zito, M. A1 - Baussan, E. A1 - Bobeth, C. A1 - Bouquerel, E. A1 - Dracos, M. A1 - Gaudiot, G. A1 - Lepers, B. A1 - Osswald, F. A1 - Poussot, P. A1 - Vassilopoulos, N. A1 - Wurtz, J. A1 - Zeter, V. A1 - Bielski, J. A1 - Kozien, M. A1 - Lacny, L. A1 - Skoczen, B. A1 - Szybinski, B. A1 - Ustrycka, A. A1 - Wroblewski, A. A1 - Marie-Jeanne, M. A1 - Balint, P. A1 - Fourel, C. A1 - Giraud, J. A1 - Jacob, J. A1 - Lamy, T. A1 - Latrasse, L. A1 - Sortais, P. A1 - Thuillier, T. A1 - Mitrofanov, S. A1 - Loiselet, M. A1 - Keutgen, Th. A1 - Delbar, Th. A1 - Debray, F. A1 - Trophine, C. A1 - Veys, S. A1 - Daversin, C. A1 - Zorin, V. A1 - Izotov, I. A1 - Skalyga, V. A1 - Burt, G. A1 - Dexter, A. C. A1 - Kravchuk, V. L. A1 - Marchi, T. A1 - Cinausero, M. A1 - Gramegna, F. A1 - De Angelis, G. A1 - Prete, G. A1 - Collazuol, G. A1 - Laveder, M. A1 - Mazzocco, M. A1 - Mezzetto, M. A1 - Signorini, C. A1 - Vardaci, E. A1 - Di Nitto, A. A1 - Brondi, A. A1 - La Rana, G. A1 - Migliozzi, P. A1 - Moro, R. A1 - Palladino, V. A1 - Gelli, N. A1 - Berkovits, D. A1 - Hass, M. A1 - Hirsh, T. Y. A1 - Schuhmann, M. A1 - Stahl, A. A1 - Wehner, J. A1 - Bross, A. A1 - Kopp, J. A1 - Neuffer, D. A1 - Wands, R. A1 - Bayes, R. A1 - Laing, A. A1 - Soler, P. A1 - Agarwalla, S. K. A1 - Cervera Villanueva, A. A1 - Donini, A. A1 - Ghosh, T. A1 - Gómez Cadenas, J. J. A1 - Hernández, P. A1 - Martín-Albo, J. A1 - Mena, O. A1 - Burguet-Castell, J. A1 - Agostino, L. A1 - Buizza-Avanzini, M. A1 - Marafini, M. A1 - Patzak, T. A1 - Tonazzo, A. A1 - Duchesneau, D. A1 - Mosca, L. A1 - Bogomilov, M. A1 - Karadzhov, Y. A1 - Matev, R. A1 - Tsenov, R. A1 - Akhmedov, E. A1 - Blennow, M. A1 - Lindner, M. A1 - Schwetz, T. A1 - Fernández Martinez, E. A1 - Maltoni, M. A1 - Menéndez, J. A1 - Giunti, C. A1 - González García, M. C. A1 - Salvado, J. A1 - Coloma, P. A1 - Huber, P. A1 - Li, T. A1 - López Pavón, J. A1 - Orme, C. A1 - Pascoli, S. A1 - Meloni, D. A1 - Tang, J. A1 - Winter, W. A1 - Ohlsson, T. A1 - Zhang, H. A1 - Scotto-Lavina, L. A1 - Terranova, F. A1 - Bonesini, M. A1 - Tortora, L. A1 - Alekou, A. A1 - Aslaninejad, M. A1 - Bontoiu, C. A1 - Kurup, A. A1 - Jenner, L. J. A1 - Long, K. A1 - Pasternak, J. A1 - Pozimski, J. A1 - Back, J. J. A1 - Harrison, P. A1 - Beard, K. A1 - Bogacz, A. A1 - Berg, J. S. A1 - Stratakis, D. A1 - Witte, H. A1 - Snopok, P. A1 - Bliss, N. A1 - Cordwell, M. A1 - Moss, A. A1 - Pattalwar, S. A1 - Apollonio, M. T1 - High intensity neutrino oscillation facilities in Europe JF - Physical Review Special Topics-Accelerators and Beams N2 - The EUROnu project has studied three possible options for future, high intensity neutrino oscillation facilities in Europe. The first is a Super Beam, in which the neutrinos come from the decay of pions created by bombarding targets with a 4 MW proton beam from the CERN High Power Superconducting Proton Linac. The far detector for this facility is the 500 kt MEMPHYS water Cherenkov, located in the Frejus tunnel. The second facility is the Neutrino Factory, in which the neutrinos come from the decay of mu(+) and mu(-) beams in a storage ring. The far detector in this case is a 100 kt magnetized iron neutrino detector at a baseline of 2000 km. The third option is a Beta Beam, in which the neutrinos come from the decay of beta emitting isotopes, in particular He-6 and Ne-18, also stored in a ring. The far detector is also the MEMPHYS detector in the Frejus tunnel. EUROnu has undertaken conceptual designs of these facilities and studied the performance of the detectors. Based on this, it has determined the physics reach of each facility, in particular for the measurement of CP violation in the lepton sector, and estimated the cost of construction. These have demonstrated that the best facility to build is the Neutrino Factory. However, if a powerful proton driver is constructed for another purpose or if the MEMPHYS detector is built for astroparticle physics, the Super Beam also becomes very attractive. KW - EMMA KW - beta-beam Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126611 VL - 16 IS - 2 ER - TY - JOUR A1 - Carsten A., Böger A1 - Gorski, Mathias A1 - Li, Man A1 - Hoffmann, Michael M. A1 - Huang, Chunmei A1 - Yang, Qiong A1 - Teumer, Alexander A1 - Krane, Vera A1 - O'Seaghdha, Conall M. A1 - Kutalik, Zoltán A1 - Wichmann, H.-Erich A1 - Haak, Thomas A1 - Boes, Eva A1 - Coassin, Stefan A1 - Coresh, Josef A1 - Kollerits, Barbara A1 - Haun, Margot A1 - Paulweber, Bernhard A1 - Köttgen, Anna A1 - Li, Guo A1 - Shlipak, Michael G. A1 - Powe, Neil A1 - Hwang, Shih-Jen A1 - Dehghan, Abbas A1 - Rivadeneira, Fernando A1 - Uitterlinden, André A1 - Hofman, Albert A1 - Beckmann, Jacques S. A1 - Krämer, Bernhard K. A1 - Witteman, Jacqueline A1 - Bochud, Murielle A1 - Siscovick, David A1 - Rettig, Rainer A1 - Kronenberg, Florian A1 - Wanner, Christoph A1 - Thadhani, Ravi I. A1 - Heid, Iris M. A1 - Fox, Caroline S. A1 - Kao, W.H. T1 - Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD JF - PLoS Genetics N2 - Family studies suggest a genetic component to the etiology of chronic kidney disease (CKD) and end stage renal disease (ESRD). Previously, we identified 16 loci for eGFR in genome-wide association studies, but the associations of these single nucleotide polymorphisms (SNPs) for incident CKD or ESRD are unknown. We thus investigated the association of these loci with incident CKD in 26,308 individuals of European ancestry free of CKD at baseline drawn from eight population-based cohorts followed for a median of 7.2 years (including 2,122 incident CKD cases defined as eGFR < 60ml/min/1.73m(2) at follow-up) and with ESRD in four case-control studies in subjects of European ancestry (3,775 cases, 4,577 controls). SNPs at 11 of the 16 loci (UMOD, PRKAG2, ANXA9, DAB2, SHROOM3, DACH1, STC1, SLC34A1, ALMS1/NAT8, UBE2Q2, and GCKR) were associated with incident CKD; p-values ranged from p = 4.1e-9 in UMOD to p = 0.03 in GCKR. After adjusting for baseline eGFR, six of these loci remained significantly associated with incident CKD (UMOD, PRKAG2, ANXA9, DAB2, DACH1, and STC1). SNPs in UMOD (OR = 0.92, p = 0.04) and GCKR (OR = 0.93, p = 0.03) were nominally associated with ESRD. In summary, the majority of eGFR-related loci are either associated or show a strong trend towards association with incident CKD, but have modest associations with ESRD in individuals of European descent. Additional work is required to characterize the association of genetic determinants of CKD and ESRD at different stages of disease progression. KW - Chronic Kidney-disease KW - Stage renal-disease KW - Glomerular-filtration-rate KW - Diabetic-nephropathy KW - General-population KW - African-americans KW - Risk KW - Progression KW - Mortality KW - Variants Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133758 VL - 7 IS - 9 ER - TY - JOUR A1 - Iyengar, Sudha K. A1 - Sedor, John R. A1 - Freedman, Barry I. A1 - Kao, W. H. Linda A1 - Kretzler, Matthias A1 - Keller, Benjamin J. A1 - Abboud, Hanna E. A1 - Adler, Sharon G. A1 - Best, Lyle G. A1 - Bowden, Donald W. A1 - Burlock, Allison A1 - Chen, Yii-Der Ida A1 - Cole, Shelley A. A1 - Comeau, Mary E. A1 - Curtis, Jeffrey M. A1 - Divers, Jasmin A1 - Drechsler, Christiane A1 - Duggirala, Ravi A1 - Elston, Robert C. A1 - Guo, Xiuqing A1 - Huang, Huateng A1 - Hoffmann, Michael Marcus A1 - Howard, Barbara V. A1 - Ipp, Eli A1 - Kimmel, Paul L. A1 - Klag, Michael J. A1 - Knowler, William C. A1 - Kohn, Orly F. A1 - Leak, Tennille S. A1 - Leehey, David J. A1 - Li, Man A1 - Malhotra, Alka A1 - März, Winfried A1 - Nair, Viji A1 - Nelson, Robert G. A1 - Nicholas, Susanne B. A1 - O’Brien, Stephen J. A1 - Pahl, Madeleine V. A1 - Parekh, Rulan S. A1 - Pezzolesi, Marcus G. A1 - Rasooly, Rebekah S. A1 - Rotimi, Charles N. A1 - Rotter, Jerome I. A1 - Schelling, Jeffrey R. A1 - Seldin, Michael F. A1 - Shah, Vallabh O. A1 - Smiles, Adam M. A1 - Smith, Michael W. A1 - Taylor, Kent D. A1 - Thameem, Farook A1 - Thornley-Brown, Denyse P. A1 - Truitt, Barbara J. A1 - Wanner, Christoph A1 - Weil, E. Jennifer A1 - Winkler, Cheryl A. A1 - Zager, Philip G. A1 - Igo, Jr, Robert P. A1 - Hanson, Robert L. A1 - Langefeld, Carl D. T1 - Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: Family Investigation of Nephropathy and Diabetes (FIND) JF - PLoS Genetics N2 - Diabetic kidney disease (DKD) is the most common etiology of chronic kidney disease (CKD) in the industrialized world and accounts for much of the excess mortality in patients with diabetes mellitus. Approximately 45% of U.S. patients with incident end-stage kidney disease (ESKD) have DKD. Independent of glycemic control, DKD aggregates in families and has higher incidence rates in African, Mexican, and American Indian ancestral groups relative to European populations. The Family Investigation of Nephropathy and Diabetes (FIND) performed a genome-wide association study (GWAS) contrasting 6,197 unrelated individuals with advanced DKD with healthy and diabetic individuals lacking nephropathy of European American, African American, Mexican American, or American Indian ancestry. A large-scale replication and trans-ethnic meta-analysis included 7,539 additional European American, African American and American Indian DKD cases and non-nephropathy controls. Within ethnic group meta-analysis of discovery GWAS and replication set results identified genome-wide significant evidence for association between DKD and rs12523822 on chromosome 6q25.2 in American Indians (P = 5.74x10\(^{−9}\)). The strongest signal of association in the trans-ethnic meta-analysis was with a SNP in strong linkage disequilibrium with rs12523822 (rs955333; P = 1.31x10\(^{−8}\)), with directionally consistent results across ethnic groups. These 6q25.2 SNPs are located between the SCAF8 and CNKSR3 genes, a region with DKD relevant changes in gene expression and an eQTL with IPCEF1, a gene co-translated with CNKSR3. Several other SNPs demonstrated suggestive evidence of association with DKD, within and across populations. These data identify a novel DKD susceptibility locus with consistent directions of effect across diverse ancestral groups and provide insight into the genetic architecture of DKD. KW - diabetic kidney disease KW - genome-wide association study KW - Family Investigation of Nephropathy and Diabetes Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-180545 VL - 11 IS - 8 ER - TY - JOUR A1 - Gessler, Manfred A1 - König, A. A1 - Arden, K. A1 - Grundy, P. A1 - Orkin, S. H. A1 - Sallan, S. A1 - Peters, C. A1 - Ruyle, S. A1 - Mandell, J. A1 - Li, F. A1 - Cavenee, W. A1 - Bruns, G. A. T1 - Infrequent mutation of the WT1 gene in 77 Wilms' Tumors N2 - Homozygous deletions in Wilms' tumor DNA have been a key step in the identification and isolation of the WTI gene. Several additional loci are also postulated to contribute to Wilms' tumor formation. To assess the frequency of WTI alterations we have analyzed the WTI locus in a panel of 77 Wilms' tumors. Eight tumors showed evidence for large deletions of several hundred or thousand kilobasepairs of DNA, some of which were also cytogenetically detected. Additional intragenic mutations were detected using more sensitive SSCP analyses to scan all 10 WTI exons. Most of these result in premature stop codons or missense mutations that inactivate the remaining WTI allele. The overall frequency of WTI alterations detected with these methods is less than 15%. While some mutations may not be detectable with the methods employed, our results suggest that direct alterations of the WTI gene are present in only a small fraction of Wilms' tumors. Thus, mutations at other Wilms' tumor loci or disturbance of interactions between these genes likely play an important role in Wilms' tumor development. KW - Wilms' tumor KW - WTI KW - Zinc finger gene KW - Tumor suppressor gene KW - Nephroblastoma KW - Deletion analysis KW - SSCP analysis KW - Mutation screening Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-34308 ER - TY - JOUR A1 - Lesch, K. P. A1 - Stöber, Gerald A1 - Balling, U. A1 - Franzek, Ernst A1 - Li, S. H. A1 - Ross, C. A. A1 - Newman, M. A1 - Beckmann, H. A1 - Riederer, P. T1 - Triplet repeats in clinical subtypes of schizophrenia: variation at the DRPLA (B37 CAG repeat) locus is not associated with periodic catatonia N2 - Clinical evidence for a dominant mode of inheritance and anticipation in periodic catatonia, a distinct subtype of schizophrenia, indicates that genes with triplet repeat expansions or other unstable repetitive elements affecting gene expression may be involved in the etiology of this disorder. Because patients affected with dentatorubral-pallidoluysian atrophy (DRPLA) may present with "schizophrenic" symptoms, we have investigated the DRPLA (B 37 CAG repeat) locus on chromosome 12 in 41 patients with periodic catatonia. The B 37 CAG repeat locus was highly polymorphic but all alleles in both the patient and control group had repeat sizes within the normal range. We conclude that variation at the DRPLA locus is unlikely to be associated with periodic catatonia. The evidence for dominant inheritance and anticipation as well as the high prevalence of human brain genes containing trinucleotide repeats justifies further screening for triplet repeat expansions in periodic catatonia. KW - Schizophrenie KW - Association study KW - B 37 CAG repeat locus KW - chromosome 12 KW - schizophrenia KW - periodic catatonia Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-63369 ER - TY - JOUR A1 - Mitchell, Jonathan S. A1 - Li, Ni A1 - Weinhold, Niels A1 - Försti, Asta A1 - Ali, Mina A1 - van Duin, Mark A1 - Thorleifsson, Gudmar A1 - Johnson, David C. A1 - Chen, Bowang A1 - Halvarsson, Britt-Marie A1 - Gudbjartsson, Daniel F. A1 - Kuiper, Rowan A1 - Stephens, Owen W. A1 - Bertsch, Uta A1 - Broderick, Peter A1 - Campo, Chiara A1 - Einsele, Hermann A1 - Gregory, Walter A. A1 - Gullberg, Urban A1 - Henrion, Marc A1 - Hillengass, Jens A1 - Hoffmann, Per A1 - Jackson, Graham H. A1 - Johnsson, Ellinor A1 - Jöud, Magnus A1 - Kristinsson, Sigurdur Y. A1 - Lenhoff, Stig A1 - Lenive, Oleg A1 - Mellqvist, Ulf-Henrik A1 - Migliorini, Gabriele A1 - Nahi, Hareth A1 - Nelander, Sven A1 - Nickel, Jolanta A1 - Nöthen, Markus M. A1 - Rafnar, Thorunn A1 - Ross, Fiona M. A1 - da Silva Filho, Miguel Inacio A1 - Swaminathan, Bhairavi A1 - Thomsen, Hauke A1 - Turesson, Ingemar A1 - Vangsted, Annette A1 - Vogel, Ulla A1 - Waage, Anders A1 - Walker, Brian A. A1 - Wihlborg, Anna-Karin A1 - Broyl, Annemiek A1 - Davies, Faith E. A1 - Thorsteinsdottir, Unnur A1 - Langer, Christian A1 - Hansson, Markus A1 - Kaiser, Martin A1 - Sonneveld, Pieter A1 - Stefansson, Kari A1 - Morgan, Gareth J. A1 - Goldschmidt, Hartmut A1 - Hemminki, Kari A1 - Nilsson, Björn A1 - Houlston, Richard S. T1 - Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JF - Nature Communications N2 - Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P=1.31 × 10−8), 6q21 (rs9372120, P=9.09 × 10−15), 7q36.1 (rs7781265, P=9.71 × 10−9), 8q24.21 (rs1948915, P=4.20 × 10−11), 9p21.3 (rs2811710, P=1.72 × 10−13), 10p12.1 (rs2790457, P=1.77 × 10−8), 16q23.1 (rs7193541, P=5.00 × 10−12) and 20q13.13 (rs6066835, P=1.36 × 10−13), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development. KW - Cancer genetics KW - Genome-wide association studies KW - Myeloma Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-165983 VL - 7 ER - TY - JOUR A1 - Dörk, Thilo A1 - Peterlongo, Peter A1 - Mannermaa, Arto A1 - Bolla, Manjeet K. A1 - Wang, Qin A1 - Dennis, Joe A1 - Ahearn, Thomas A1 - Andrulis, Irene L. A1 - Anton-Culver, Hoda A1 - Arndt, Volker A1 - Aronson, Kristan J. A1 - Augustinsson, Annelie A1 - Beane Freeman, Laura E. A1 - Beckmann, Matthias W. A1 - Beeghly-Fadiel, Alicia A1 - Behrens, Sabine A1 - Bermisheva, Marina A1 - Blomqvist, Carl A1 - Bogdanova, Natalia V. A1 - Bojesen, Stig E. A1 - Brauch, Hiltrud A1 - Brenner, Hermann A1 - Burwinkel, Barbara A1 - Canzian, Federico A1 - Chan, Tsun L. A1 - Chang-Claude, Jenny A1 - Chanock, Stephen J. A1 - Choi, Ji-Yeob A1 - Christiansen, Hans A1 - Clarke, Christine L. A1 - Couch, Fergus J. A1 - Czene, Kamila A1 - Daly, Mary B. A1 - dos-Santos-Silva, Isabel A1 - Dwek, Miriam A1 - Eccles, Diana M. A1 - Ekici, Arif B. A1 - Eriksson, Mikael A1 - Evans, D. Gareth A1 - Fasching, Peter A. A1 - Figueroa, Jonine A1 - Flyger, Henrik A1 - Fritschi, Lin A1 - Gabrielson, Marike A1 - Gago-Dominguez, Manuela A1 - Gao, Chi A1 - Gapstur, Susan M. A1 - García-Closas, Montserrat A1 - García-Sáenz, José A. A1 - Gaudet, Mia M. A1 - Giles, Graham G. A1 - Goldberg, Mark S. A1 - Goldgar, David E. A1 - Guenél, Pascal A1 - Haeberle, Lothar A1 - Haimann, Christopher A. A1 - Håkansson, Niclas A1 - Hall, Per A1 - Hamann, Ute A1 - Hartman, Mikael A1 - Hauke, Jan A1 - Hein, Alexander A1 - Hillemanns, Peter A1 - Hogervorst, Frans B. L. A1 - Hooning, Maartje J. A1 - Hopper, John L. A1 - Howell, Tony A1 - Huo, Dezheng A1 - Ito, Hidemi A1 - Iwasaki, Motoki A1 - Jakubowska, Anna A1 - Janni, Wolfgang A1 - John, Esther M. A1 - Jung, Audrey A1 - Kaaks, Rudolf A1 - Kang, Daehee A1 - Kapoor, Pooja Middha A1 - Khusnutdinova, Elza A1 - Kim, Sung-Won A1 - Kitahara, Cari M. A1 - Koutros, Stella A1 - Kraft, Peter A1 - Kristensen, Vessela N. A1 - Kwong, Ava A1 - Lambrechts, Diether A1 - Le Marchand, Loic A1 - Li, Jingmei A1 - Lindström, Sara A1 - Linet, Martha A1 - Lo, Wing-Yee A1 - Long, Jirong A1 - Lophatananon, Artitaya A1 - Lubiński, Jan A1 - Manoochehri, Mehdi A1 - Manoukian, Siranoush A1 - Margolin, Sara A1 - Martinez, Elena A1 - Matsuo, Keitaro A1 - Mavroudis, Dimitris A1 - Meindl, Alfons A1 - Menon, Usha A1 - Milne, Roger L. A1 - Mohd Taib, Nur Aishah A1 - Muir, Kenneth A1 - Mulligan, Anna Marie A1 - Neuhausen, Susan L. A1 - Nevanlinna, Heli A1 - Neven, Patrick A1 - Newman, William G. A1 - Offit, Kenneth A1 - Olopade, Olufunmilayo I. A1 - Olshan, Andrew F. A1 - Olson, Janet E. A1 - Olsson, Håkan A1 - Park, Sue K. A1 - Park-Simon, Tjoung-Won A1 - Peto, Julian A1 - Plaseska-Karanfilska, Dijana A1 - Pohl-Rescigno, Esther A1 - Presneau, Nadege A1 - Rack, Brigitte A1 - Radice, Paolo A1 - Rashid, Muhammad U. A1 - Rennert, Gad A1 - Rennert, Hedy S. A1 - Romero, Atocha A1 - Ruebner, Matthias A1 - Saloustros, Emmanouil A1 - Schmidt, Marjanka K. A1 - Schmutzler, Rita K. A1 - Schneider, Michael O. A1 - Schoemaker, Minouk J. A1 - Scott, Christopher A1 - Shen, Chen-Yang A1 - Shu, Xiao-Ou A1 - Simard, Jaques A1 - Slager, Susan A1 - Smichkoska, Snezhana A1 - Southey, Melissa C. A1 - Spinelli, John J. A1 - Stone, Jennifer A1 - Surowy, Harald A1 - Swerdlow, Anthony J. A1 - Tamimi, Rulla M. A1 - Tapper, William J. A1 - Teo, Soo H. A1 - Terry, Mary Beth A1 - Toland, Amanda E. A1 - Tollenaar, Rob A. E. M. A1 - Torres, Diana A1 - Torres-Mejía, Gabriela A1 - Troester, Melissa A. A1 - Truong, Thérèse A1 - Tsugane, Shoichiro A1 - Untch, Michael A1 - Vachon, Celine M. A1 - van den Ouweland, Ans M. W. A1 - van Veen, Elke M. A1 - Vijai, Joseph A1 - Wendt, Camilla A1 - Wolk, Alicja A1 - Yu, Jyh-Cherng A1 - Zheng, Wei A1 - Ziogas, Argyrios A1 - Ziv, Elad A1 - Dunnig, Alison A1 - Pharaoh, Paul D. P. A1 - Schindler, Detlev A1 - Devilee, Peter A1 - Easton, Douglas F. T1 - Two truncating variants in FANCC and breast cancer risk JF - Scientific Reports N2 - Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk associations of others remain unknown. The gene for FA type C, FANCC, has been proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. We used the Oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 95%CI 0.44–1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations. If this applies to all truncating variants in FANCC it would suggest there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit of large consortia for clarifying risk associations of rare variants. KW - oncology KW - risk factors Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222838 VL - 9 ER - TY - JOUR A1 - Marenholz, Ingo A1 - Esparza-Gordillo, Jorge A1 - Rüschendorf, Franz A1 - Bauerfeind, Anja A1 - Strachan, David P. A1 - Spycher, Ben D. A1 - Baurecht, Hansjörg A1 - Magaritte-Jeannin, Patricia A1 - Sääf, Annika A1 - Kerkhof, Marjan A1 - Ege, Markus A1 - Baltic, Svetlana A1 - Matheson, Melanie C. A1 - Li, Jin A1 - Michel, Sven A1 - Ang, Wei Q. A1 - McArdle, Wendy A1 - Arnold, Andreas A1 - Homuth, Georg A1 - Demenais, Florence A1 - Bouzigon, Emmanuelle A1 - Söderhäll, Cilla A1 - Pershagen, Göran A1 - de Jongste, Johan C. A1 - Postma, Dirkje S. A1 - Braun-Fahrländer, Charlotte A1 - Horak, Elisabeth A1 - Ogorodova, Ludmila M. A1 - Puzyrev, Valery P. A1 - Bragina, Elena Yu A1 - Hudson, Thomas J. A1 - Morin, Charles A1 - Duffy, David L. A1 - Marks, Guy B. A1 - Robertson, Colin F. A1 - Montgomery, Grant W. A1 - Musk, Bill A1 - Thompson, Philip J. A1 - Martin, Nicholas G. A1 - James, Alan A1 - Sleiman, Patrick A1 - Toskala, Elina A1 - Rodriguez, Elke A1 - Fölster-Holst, Regina A1 - Franke, Andre A1 - Lieb, Wolfgang A1 - Gieger, Christian A1 - Heinzmann, Andrea A1 - Rietschel, Ernst A1 - Keil, Thomas A1 - Cichon, Sven A1 - Nöthen, Markus M. A1 - Pennel, Craig E. A1 - Sly, Peter D. A1 - Schmidt, Carsten O. A1 - Matanovic, Anja A1 - Schneider, Valentin A1 - Heinig, Matthias A1 - Hübner, Norbert A1 - Holt, Patrick G. A1 - Lau, Susanne A1 - Kabesch, Michael A1 - Weidinger, Stefan A1 - Hakonarson, Hakon A1 - Ferreira, Manuel A. R. A1 - Laprise, Catherine A1 - Freidin, Maxim B. A1 - Genuneit, Jon A1 - Koppelman, Gerard H. A1 - Melén, Erik A1 - Dizier, Marie-Hélène A1 - Henderson, A. John A1 - Lee, Young Ae T1 - Meta-analysis identifies seven susceptibility loci involved in the atopic march JF - Nature Communications N2 - Eczema often precedes the development of asthma in a disease course called the 'atopic march'. To unravel the genes underlying this characteristic pattern of allergic disease, we conduct a multi-stage genome-wide association study on infantile eczema followed by childhood asthma in 12 populations including 2,428 cases and 17,034 controls. Here we report two novel loci specific for the combined eczema plus asthma phenotype, which are associated with allergic disease for the first time; rs9357733 located in EFHC1 on chromosome 6p12.3 (OR 1.27; P = 2.1 x 10(-8)) and rs993226 between TMTC2 and SLC6A15 on chromosome 12q21.3 (OR 1.58; P = 5.3 x 10(-9)). Additional susceptibility loci identified at genome-wide significance are FLG (1q21.3), IL4/KIF3A (5q31.1), AP5B1/OVOL1 (11q13.1), C11orf30/LRRC32 (11q13.5) and IKZF3 (17q21). We show that predominantly eczema loci increase the risk for the atopic march. Our findings suggest that eczema may play an important role in the development of asthma after eczema. KW - chromosome 11Q13 KW - risk KW - genomewide association KW - hay fever KW - birth cohort KW - filaggrin mutations KW - food allergy KW - juvenile myoclonic epilepsy KW - childhood asthma KW - dermatitis Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-139835 VL - 6 IS - 8804 ER -